We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has warned Indian generic company Aurobindo Pharma for GMP violations and is requesting a detailed action plan for improving packaging and labeling compliance.